Update on FDA Advisory Committee Vote on Camizestrant in Combination With a CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
May 01, 2026
May 01, 2026
WILMINGTON, Delaware, May 1 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a . . .
* * *
Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer
The US Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote in favor of the benefit risk profile of AstraZeneca's camizestrant in combination with a . . .